Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4884942 | 0.85 | MLYCD (1.00) | MLYCD | |
| SCHEMBL4420296 | 0.84 | MLYCD (1.00) | MLYCDMAPT | |
| SCHEMBL4425493 | 0.82 | MLYCD (1.00) | MLYCD | |
| SCHEMBL4417925 | 0.81 | MLYCD (1.00) | MLYCD | |
| SCHEMBL4431614 | 0.80 | MLYCD (1.00) | MLYCD | |
| SCHEMBL4873346 | 0.80 | MLYCD (0.73) | MLYCD | |
| SCHEMBL4427643 | 0.79 | MLYCD (1.00) | MLYCD | |
| SCHEMBL4422409 | 0.79 | MLYCD (1.00) | MLYCD | |
| SCHEMBL4880733 | 0.78 | MLYCD (0.68) | MLYCD | |
| SCHEMBL4431570 | 0.78 | MLYCD (1.00) | MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070869-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-03-20 | — | — | US | claimed |
| US-7279477-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-10-09 | — | — | US | claimed |
| US-20040063671-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063671-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | MLYCD, ACACA, ME1 | MLYCD 1/4885MAPT 1971/4885 |
| US-20080070869-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | MLYCD, ME3, ACACA | MLYCD 1/4885MAPT 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.